Criticism of BREXAFEMME Development from SCYNEXIS!

Jersey City, N.J., November 19, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company that develops innovative therapies to overcome and prevent difficult-to-treat and drug-resistant infections, announced the transfer of the New Drug Application (NDA) for BREXAFEMME (ibrexafungerp) to GSK.

SCYNEXIS's CEO, Dr. David Angulo, stated, "We are pleased to have completed the transfer of the BREXAFEMME NDA. With the completion of this transfer, GSK will be able to begin discussions with the U.S. Food and Drug Administration (FDA) regarding the reintroduction of BREXAFEMME for vulvovaginal candidiasis and recurrent vulvovaginal candidiasis." He added, "Additionally, SCYNEXIS anticipates receiving significant non-dilutive capital sources through net sales milestones and royalties following the reintroduction."

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company that develops innovative therapies to prevent and overcome difficult-to-treat infections. The company aims to help millions of patients worldwide. SCYNEXIS is working on its proprietary antifungal platform "fungerps," with ibrexafungerp being the first representative of this new class, licensed to GSK. The FDA has approved BREXAFEMME® (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis and for reducing the frequency of recurrent vulvovaginal candidiasis. Other antifungal assets in this new class are in clinical, pre-clinical, and discovery phases, including the compound SCY-247.